CO2018004882A2 - Integración de las características tumorales con el índice de cáncer de mama - Google Patents

Integración de las características tumorales con el índice de cáncer de mama

Info

Publication number
CO2018004882A2
CO2018004882A2 CONC2018/0004882A CO2018004882A CO2018004882A2 CO 2018004882 A2 CO2018004882 A2 CO 2018004882A2 CO 2018004882 A CO2018004882 A CO 2018004882A CO 2018004882 A2 CO2018004882 A2 CO 2018004882A2
Authority
CO
Colombia
Prior art keywords
breast cancer
integration
methods
tumor characteristics
cancer index
Prior art date
Application number
CONC2018/0004882A
Other languages
English (en)
Inventor
Catherine A Schnabel
Yi Zhang
Original Assignee
Biotheranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheranostics Inc filed Critical Biotheranostics Inc
Publication of CO2018004882A2 publication Critical patent/CO2018004882A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Se proporcionan métodos para determinar el riesgo de recurrencia de un cáncer de mama de un sujeto. También se proporcionan métodos para predecir la capacidad de respuesta a una terapia de cáncer de mama de un sujeto. Además, se proporcionan métodos para recomendar el tratamiento de un sujeto que tenga cáncer de mama. También se proporcionan métodos para tratar un sujeto que tenga cáncer de mama. Se proporcionan también sistemas para llevar a cabo los métodos descritos.
CONC2018/0004882A 2015-11-13 2018-05-08 Integración de las características tumorales con el índice de cáncer de mama CO2018004882A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255260P 2015-11-13 2015-11-13
US201562265964P 2015-12-10 2015-12-10
PCT/US2016/061568 WO2017083675A1 (en) 2015-11-13 2016-11-11 Integration of tumor characteristics with breast cancer index

Publications (1)

Publication Number Publication Date
CO2018004882A2 true CO2018004882A2 (es) 2018-08-10

Family

ID=58690472

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004882A CO2018004882A2 (es) 2015-11-13 2018-05-08 Integración de las características tumorales con el índice de cáncer de mama

Country Status (7)

Country Link
US (2) US11530448B2 (es)
EP (1) EP3374526A4 (es)
BR (1) BR112018009528A2 (es)
CO (1) CO2018004882A2 (es)
IL (1) IL259241B2 (es)
MX (1) MX2018005867A (es)
WO (1) WO2017083675A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108492884A (zh) * 2018-02-08 2018-09-04 浙江大学 基于Logistic回归模型的胰腺神经内分泌肿瘤淋巴结转移预测系统
CN108364106A (zh) * 2018-02-27 2018-08-03 平安科技（深圳）有限公司 一种报销单风险预测方法、装置、终端设备及存储介质
CN109272843A (zh) * 2018-11-23 2019-01-25 神农架林区人民医院 用于乳腺触诊的模拟训练装置
WO2022214564A1 (en) 2021-04-06 2022-10-13 Institut Curie Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling
EP4334475A1 (en) * 2021-05-07 2024-03-13 Agendia N.V. Endocrine treatment of hormone receptor positive breast cancer typed as having a low risk of recurrence

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981783A (en) 1986-04-16 1991-01-01 Montefiore Medical Center Method for detecting pathological conditions
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6482600B1 (en) 1998-05-07 2002-11-19 Lifespan Biosciences, Inc. Breast cancer associated nucleic acid sequences and their associated proteins
US6328709B1 (en) 1998-11-13 2001-12-11 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
AU2001229637A1 (en) 2000-01-21 2001-07-31 Thomas Jefferson University Nipple aspirate fluid specific microarrays
CA2414650A1 (en) 2000-06-30 2002-01-10 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
US6673024B2 (en) 2000-07-28 2004-01-06 Angela Soito Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage
US20030049701A1 (en) 2000-09-29 2003-03-13 Muraca Patrick J. Oncology tissue microarrays
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP1470239B1 (en) 2001-12-31 2009-12-30 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
EP3470535B1 (en) 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
BRPI0414553A (pt) 2003-09-19 2006-11-07 Arcturus Bioscience Inc previsão do resultado de tratamento contra o cáncer de mama
CA2569698A1 (en) 2004-06-04 2006-01-12 Mark G. Erlander The importance of the gene hoxb13 for cancer
EP1880335A1 (en) 2005-05-13 2008-01-23 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
CN101297045A (zh) 2005-06-03 2008-10-29 阿威亚拉德克斯股份有限公司 肿瘤和组织的鉴定
CA2698569A1 (en) 2007-09-06 2009-09-03 Mark G. Erlander Tumor grading and cancer prognosis
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
JP6147755B2 (ja) 2011-11-08 2017-06-14 ジェノミック ヘルス， インコーポレイテッド 乳癌の予後を予測する方法
WO2015035377A1 (en) * 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
EP3044335B1 (en) 2013-09-11 2020-09-09 Bio Theranostics, Inc. Predicting breast cancer recurrence
WO2015184182A1 (en) 2014-05-29 2015-12-03 Biotheranostics, Inc Predicting likelihood of response to combination therapy

Also Published As

Publication number Publication date
IL259241B2 (en) 2024-04-01
US11530448B2 (en) 2022-12-20
EP3374526A4 (en) 2019-09-11
IL259241A (en) 2018-07-31
US20170137891A1 (en) 2017-05-18
US20230083179A1 (en) 2023-03-16
MX2018005867A (es) 2018-09-21
EP3374526A1 (en) 2018-09-19
BR112018009528A2 (pt) 2018-11-06
IL259241B1 (en) 2023-12-01
WO2017083675A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
CO2018004882A2 (es) Integración de las características tumorales con el índice de cáncer de mama
NI201900019A (es) Inhibidores de procesos metabólicos celulares
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
ECSP15026557A (es) Compuestos y sus métodos de empleo
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016002798A1 (es) Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón.
EA201400178A1 (ru) Лечение рака молочной железы
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
MX2021002014A (es) Metodo para determinar el riesgo de recidiva de cancer de mama.
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
EA201791897A1 (ru) α-МИКРОГЛОБУЛИН ДЛЯ ИСПОЛЬЗОВАНИЯ В ЗАЩИТЕ ПОЧЕК ПРИ РАДИОНУКЛИДНОЙ ТЕРАПИИ
CO2020008319A2 (es) Métodos para tratar la enfermedad de gaucher
EA201990411A1 (ru) Способы лечения рака предстательной железы